Fractyl Health secures U.S. patent for Revita catheter with protection through 2042
GUTS•Fractyl Health received a U.S. patent covering Revita catheter design features, with protection through November 28, 2042, and the USPTO allowed an application covering the treatment’s thermal dosing method.
1. Patent protection
Fractyl Health received the catheter-design patent on September 22, 2026. The company said its portfolio includes 39 granted U.S. patents, approximately 40 pending U.S. applications and more than 50 issued international patents.
2. Revita program
Revita is advancing toward a planned FDA De Novo marketing submission for post-GLP-1 weight maintenance following positive six-month REMAIN-1 pivotal results. Existing claims covering duodenal treatment methods are not limited to a specific energy modality.
